Physics-based US software specialist Schrödinger’s shares leapt nearly 14% to $22.25 on the back of news that it has entered ...

The price trend for Novartis (NVS) has been bearish lately and the stock has lost 5.1% over the past two weeks. However, the formation of a hammer chart pattern in its last trading session indicates ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

As the COVID-19 pandemic clearly demonstrated, health is an integral part of Europe’s security. That principle underpinned a ...

https://www.tipranks.com/news/the-fly/schrodinger-announces-expanded-license-agreement-with-novartis Schrodinger (SDGR) today ...

In its recent earnings release for the third quarter of 2024, Schrödinger reported significant developments, including a new collaboration with Novartis, which will see an upfront payment of $150 ...

Atrial arrhythmias were found in 26% of patients with sickle cell disease (SCD), with a significant association with stroke history. Early detection and treatment of atrial arrhythmias may help ...

and Novartis. StudyFinds publishes digestible, agenda-free, transparent research summaries that are intended to inform the ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Alcon, whose biggest market is the U.S. making up nearly a half of its revenue, said it expected annual net sales to grow by ...

Novartis (NVS) has been beaten down lately with too much selling pressure. While the stock has lost 9.7% over the past four ...